BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published ...
Hosted on MSN17h
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorderAlterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy treatment. ... Read More The post Health Check: Alterity angles for fast-track FDA ...
Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...
To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1‐800-FDA-1088 or .
Hosted on MSN17h
Phase III Trials: It’s crunch time for these ASX health stocksSeveral ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...
The "Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Application Training Course" conference has been added to ResearchAndMarkets.com's offering. The Common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback